Gradientech announces Notice of Allowance from Chinese Patent Office

Uppsala, March 20, 2079. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Chinese Patent Office (CHN) for the patent application no. 201480038696, "New Use of a Fluidic Device".

The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacterial sample within a microfluidic controlled environment that is part of the technology platform of the Company's diagnostic system QuickMIC™ for ultra-rapid AST. A Notice of Allowance signifies that Gradientech will be entitled to receive patent protection until 2034 in China for the allowed claims when the patent is issued. Gradientech has already been granted patent protection for MIC determination in Europe and Japan.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se